Printer Friendly

I-Mab Biopharma treats the first ulcerative colitis patient in China under its phase II clinical trial of TJ301.

Global Banking News-October 12, 2018-I-Mab Biopharma treats the first ulcerative colitis patient in China under its phase II clinical trial of TJ301

(C)2018 ENPublishing - http://www.enpublishing.co.uk

Immuno-inflammation company I-Mab Biopharma revealed on Thursday that it has dosed the first patient in China under its phase II clinical trial of TJ301 for the treatment of Ulcerative Colitis (UC), a chronic inflammatory bowel disease.

The company has initiated its phase II clinical trial of TJ301 for the treatment of ulcerative colitis (UC) at the Division of Gastroenterology, the First Affiliated Hospital of Sun Yat-sen University in Guangdong, China.

According to the company, TJ301 is a phase II, randomised, double-blind, placebo-controlled study that is being conducted in multiple sites across China, South Korea and Taiwan area to evaluate the safety and efficacy of TJ301 administered intravenously in patients with active ulcerative colitis.

TJ301, a selective IL-6 blocker, works through a novel trans-signalling mechanism without interacting with either IL-6 or IL-6R individually. This mechanism of action is unique from other anti-IL6 or anti-IL6R products that block all actions of IL-6. TJ301 is expected to have a better safety profile over the existing IL-6-based biologics, added the company.

In conjunction, the company I-Mab holds the exclusive rights to TJ301 for further development and commercialisation in Greater China and South Korea under a licensing agreement with Ferring.

((Distributed via M2 Communications - http://www.m2.com))

COPYRIGHT 2018 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Global Banking News (GBN)
Geographic Code:9CHIN
Date:Oct 12, 2018
Words:233
Previous Article:Synthetic Biologics prices USD18m public offering of common stock, preferred stock & warrants.
Next Article:Capio reports preliminary Q3 2018 results.

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters